XML 92 R66.htm IDEA: XBRL DOCUMENT v2.4.0.6
Investments (Narrative) (Details)
In Millions, unless otherwise specified
12 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2010
USD ($)
Dec. 31, 2009
USD ($)
Dec. 31, 2011
USD ($)
Dec. 31, 2011
PreAnalytiX GmbH [Member]
Dec. 31, 2011
QBM Cell Science
Dec. 31, 2011
QIAGEN Finance [Member]
Aug. 31, 2004
QIAGEN Finance [Member]
USD ($)
Dec. 31, 2011
QIAGEN Euro Finance [Member]
Dec. 31, 2011
Pyrobett
Dec. 31, 2010
Pyrobett
EUR (€)
Jun. 30, 2011
Scandinavian Gene Synthesis AB [Member]
USD ($)
Dec. 31, 2011
Scandinavian Gene Synthesis AB [Member]
Dec. 31, 2011
Dx Assays Pte Ltd
USD ($)
Dec. 31, 2010
Dx Assays Pte Ltd
USD ($)
May 31, 2006
QIAGEN Euro Finance [Member]
Convertible Notes 3.25% Due in 2026 [Member]
USD ($)
Ownership percentage       50.00% 19.50% 100.00%   100.00% 19.00%     40.00% 33.30%    
Convertible debt             $ 150.0               $ 300.0
Stated rate of senior convertible notes             1.50%               3.25%
Payments to Acquire Equity Method Investments                     9.7        
Advance Payment, Equity Method Investment, Additional Shares Acquisition Option                     6.7        
Equity Method Investment Acquisition Option Percent                       60.00%      
Investment made in company 3.4   6.8             4.0          
Loans receivable from related party                         1.5 1.6  
Interest rate percentage on loans made to related parties                         15.00%    
Realized gain on sale of investment $ 0.6 $ 10.5